Differentially expressed genes analysis of wild type K562 cells treated with vandetanib and control (DMSO)

Purpose: The aim of this study was to evaluate the difference of mRNA and lncRNA in K562 cells treated with vandetanib (1.56 μM) and control (DMSO) by high-throughput sequencing results. Methods: Total RNA was extracted using the RNAfast200 kit according to the manufacturer’s protocol. Then, 200 ng RNA was sequenced with high throughput, and then pathway and GO analysis were used for comprehensive analysis. Finally, RT-PCR method was used to validate in large sample population. Results: High-throughput sequencing results showed that there were significant differences in mRNA and lncRNA in K562 cells treated with vandetanib (1.56 μM) and control (DMSO). Conclusions: It is the first time that we have used high-throughput sequencing to study the difference of mRNA and lncRNA in K562 cells treated with vandetanib (1.56 μM) and control (DMSO). The results of sequencing show that the expression of mRNA and lncRNA is quite different in K562 cells treated with vandetanib (1.56 μM) and control (DMSO). Three control (DMSO) treated samples and three vandetanib (1.56 μM) treated samples.